Tilt Biotherapeutics Ltd.

This early-phase trial tests a new approach for ovarian cancer that has stopped responding to platinum chemotherapy. It combines TILT-123, a virus engineered to kill cancer cells and boost immune activity, with the immunotherapy drug pembrolizumab, and in some cases also with a c…

This early-stage trial tests a new approach for advanced melanoma that has not responded to standard treatments. Nine patients will receive a modified virus (TILT-123) designed to deliver immune-boosting signals directly into tumors, along with their own tumor-fighting immune cel…

This early-stage trial tests a new treatment for people with advanced non-small cell lung cancer that no longer responds to standard immunotherapy. The treatment combines a specially designed virus (TILT-123) that delivers immune-boosting signals directly into tumors, with the im…